NDC Code | 43742-1371-1 |
Package Description | 30 mL in 1 BOTTLE, DROPPER (43742-1371-1) |
Product NDC | 43742-1371 |
Product Type Name | HUMAN OTC DRUG |
Proprietary Name | Female Stimulant |
Non-Proprietary Name | Lilium Tigrinum, Bovista, Cypripedium Pubescens, Hydrastis Canadensis, Apiolum, Apis Venenum Purum, Aquilegia Vulgaris, Funiculus Umbilicalis Suis, Glandula Suprarenalis Suis, Heart (suis), Kreosotum, Oophorinum (suis), Uterus (suis), Folliculinum, Aconiticum Acidum, Cis-, Lachesis Mutus, Magnesia Phosphorica, Mercurius Solubilis, Sepia, Pineal Gland (suis), Hypophysis Suis, Estradiol, Progesterone, Testosterone, Placenta Totalis Suis, Bacillus Faecalis, Mutabile Bacillus (bach) |
Dosage Form | LIQUID |
Usage | ORAL |
Start Marketing Date | 20190517 |
End Marketing Date | 20251023 |
Marketing Category Name | UNAPPROVED HOMEOPATHIC |
Manufacturer | Deseret Biologicals, Inc. |
Substance Name | ACONITIC ACID, (Z)-; ALCALIGENES FAECALIS; APIOLE (PARSLEY); APIS MELLIFERA VENOM; AQUILEGIA VULGARIS; CYPRIPEDIUM PARVIFLORUM VAR. PUBESCENS ROOT; ESCHERICHIA COLI; ESTRADIOL; ESTRONE; GOLDENSEAL; LACHESIS MUTA VENOM; LILIUM LANCIFOLIUM WHOLE FLOWERING; LYCOPERDON UTRIFORME FRUITING BODY; MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE; MERCURIUS SOLUBILIS; PORK HEART; PROGESTERONE; SEPIA OFFICINALIS JUICE; SUS SCROFA ADRENAL GLAND; SUS SCROFA OVARY; SUS SCROFA PINEAL GLAND; SUS SCROFA PITUITARY GLAND; SUS SCROFA PLACENTA; SUS SCROFA UMBILICAL CORD; SUS SCROFA UTERUS; TESTOSTERONE; WOOD CREOSOTE |
Strength | 10; 30; 6; 8; 8; 6; 30; 30; 8; 6; 10; 4; 6; 10; 10; 8; 30; 10; 8; 8; 12; 13; 6; 8; 8; 30; 8 |
Strength Unit | [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL |
Pharmacy Classes | Androgen Receptor Agonists [MoA], Androgen [EPC], Androstanes [CS], Calculi Dissolution Agent [EPC], Estradiol Congeners [CS], Estrogen Receptor Agonists [MoA], Estrogen [EPC], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Progesterone [CS], Progesterone [EPC], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] |
DEA Schedule | CIII |